Abstract

Microtubule-associated protein tau is the major component of the neurofibrillary tangles of Alzheimer disease (AD) and is genetically linked to frontotemporal dementias (FTDP-17). We have recently shown that tau interacts with the SH3 domain of Fyn, an Src family non-receptor tyrosine kinase, and is tyrosine-phosphorylated by Fyn on Tyr-18. Also, tyrosine-phosphorylated tau is present in the neuropathology of AD. To determine whether alterations in the tau-Fyn interaction might correlate with disease-related factors in AD and FTDP-17, we have performed real-time surface plasmon resonance studies on a panel of 21 tau constructs with Fyn SH3. We report that the interaction between Fyn SH3 and 3R-tau was 20-fold higher than that with 4R-tau. In addition, the affinity between 4R-tau and Fyn SH3 was increased 25-45-fold by phosphorylation-mimicking mutations or by FTDP-17 mutations. In vitro kinase reactions show that tau, with lower affinity SH3 interactions, exhibited a lower level of Tyr-18 phosphorylation under our reaction conditions. Lastly, we have demonstrated that tau is phosphorylated on Tyr-18 in the tau P301L mouse model for tauopathy (JNPL3). In summary, our results suggest that disease-related phosphorylation and missense mutations of tau increase association of tau with Fyn. Because these effects are mediated through the 4R component of the tau population, these results also have implications for the FTDP-17 diseases caused by increased expression of 4R-tau. Our data support a role for the Fyn-tau interaction in neurodegeneration.

Highlights

  • May have a role in the signaling events underlying neuropathology

  • 3R-tau Binds to Fyn SH3 with a Higher Affinity than 4R-tau—To investigate the interaction between Fyn and tau, we used surface plasmon resonance (SPR) spectroscopy to quantitate the interaction between tau and the SH3 domain of Fyn

  • Our earlier results demonstrated that Tyr-18 of tau was tyrosinephosphorylated early in development and that this phosphorylated form of tau existed in the neurofibrillary tangles of Alzheimer disease (AD) [2]

Read more

Summary

EXPERIMENTAL PROCEDURES

Expression of Recombinant Tau—Human tau with 3- or 4-microtubule-binding repeats (352- or 383-residue isoforms) were subcloned into either pET-3d or pET-17b vectors (Novagen, Madison, WI) for bacterial protein expression using standard techniques. The following mutations were introduced using site-directed mutagenesis (QuikChange mutagenesis kit, Stratagene, La Jolla, CA) (Fig. 1): 1) FTDP-17 missense mutations V337M, G272V, R406W, P301L, and R5H; and 2) phosphorylation-mimicking mutations S199D, S199D/ S202D, S396D, S404D, S396D/S404D, and T231D/S235D. A construct with an internal deletion of the PXXP motif (⌬P) has been previously

Interaction between Fyn and Tau
RESULTS
Wild type
TABLE TWO
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call